Journal article icon

Journal article

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms

Abstract:
Hypoxia-inducible factors (HIFs) are master transcriptional regulators, central to cellular survival in hypoxia and frequently activated within malignancy. Whilst malignant context directs the role of HIFs within oncogenesis, these mechanisms are not well characterised. Applying the JAK2V617F myeloproliferative neoplasms (MPNs) oncogene-driver model, in which HIF-1α is stabilised in normoxia (20% O2), we sought to determine whether the modality of HIF-1 activation directs its function. Through direct analysis of hypoxia-activated vs. JAK2V617F-activated HIF-1 at the chromatin, we define a JAK2V617F-HIF-1 regulon that diverges from canonical HIF/hypoxia targets. In a cohort of 172 JAK2V617F-MPN patients, we observe significant association of the JAK2V617F-HIF-1 regulon, but not canonical HIF-1 gene signatures, with disease severity, progression, and patient survival. We further define a subset gene signature (HIF1-MPN-BP) significantly associated with spontaneous transformation to blast phase MPNs. Finally, we identify that JAK2V617F-induced HIF-1α stabilisation is mediated via PIM1 kinase. Our findings demonstrate that HIF-1 activation by the JAK2V617F-PIM1 axis significantly alters HIF-1 transcription function, desensitising HIF-1 activity to cellular oxygen levels, and restricting the HIF-1 regulon to a set of disease-associated target genes within JAK2V617F-MPNs. These findings restore the potential for specific therapeutic targeting of HIF-1 by delineating malignant activation from the physiological hypoxic response.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1038/s41375-025-02843-9

Authors

More by this author
Role:
Author
ORCID:
0000-0001-9246-8134
More by this author
Role:
Author
ORCID:
0000-0001-7978-9873
More by this author
Role:
Author
ORCID:
0000-0003-4023-6635
More by this author
Role:
Author
ORCID:
0000-0001-6597-4613


More from this funder
Funder identifier:
10.13039/100004440
Grant:
302479/Z/23/Z
More from this funder
Funder identifier:
10.13039/501100000402
Grant:
KKL1377
More from this funder
Funder identifier:
10.13039/501100000265
Grant:
UKRI1444


Publisher:
Springer Nature [academic journals on nature.com]
Journal:
Leukemia More from this journal
Volume:
40
Issue:
3
Pages:
609-621
Publication date:
2026-02-02
Acceptance date:
2025-12-12
DOI:
EISSN:
1476-5551
ISSN:
0887-6924


Language:
English
Keywords:
Pubs id:
2368930
Local pid:
pubs:2368930
Source identifiers:
3822005
Deposit date:
2026-03-04
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP